Opko Health, Inc. is a diversified healthcare company operating in the pharmaceutical and diagnostics sectors. Its pharmaceutical business features NGENLA, a once-weekly human growth hormone injection for pediatric growth hormone deficiency, which is commercialized through a partnership with Pfizer in multiple global markets. The company also manufactures and sells Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism in adults with chronic kidney disease, with marketing authorizations in several European countries and ongoing development in mainland China. Through its subsidiary ModeX Therapeutics, Opko Health develops multi-specific immune therapies for cancer and infectious diseases using the MSTAR platform and Nanoparticle Vaccine technology, with clinical collaborations involving Merck and Regeneron. The diagnostics segment is centered on BioReference Health, a specialized clinical laboratory in the United States that provides core clinical testing and maintains a national specialty urology franchise, including the 4Kscore prostate cancer test. The company operates established pharmaceutical platforms in Spain, Ireland, Chile, and Mexico, with its Irish subsidiary EirGen Pharma specializing in the development and commercial supply of high-potency oral solid dose pharmaceutical products. Opko Health was originally incorporated in 1991 as Cytoclonal Pharmaceutics, Inc., later changed to eXegenics, Inc., and adopted its current name in 2007.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Drug Manufacturers - General Homepage opko.com
Sector Healthcare IR page opko.com/investors
Tags
human growth hormone, secondary hyperparathyroidism, chronic kidney disease, immuno-oncology, infectious diseases, multispecific antibodies, clinical diagnostics, urology, prostate cancer testing, oral solid dose pharmaceuticals, NGENLA, Somatrogon, Rayaldee, ModeX Therapeutics, MSTAR, Nanoparticle Vaccine, MDX2001, BioReference Health, 4Kscore, EirGen Pharma, Pfizer, Merck, Regeneron
Press page opko.com/investors/news-events/press-releases

Metrics

Valuation  
Market cap $ 1.337B
Market cap (USD) $ 1.337B
P/E -6.00
PEG —
P/BV 1.20
P/S 2.66
P/OCF -10.69
P/FCF -9.88
Dividend yield —
Turnover / mcap —
Returns  
ROE -17.1%
ROI -14.0%
ROIC -5.5%
Profit margin -37.2%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 0.25%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 44
Quality score -64.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 606.879M 713.142M 863.495M 1.004B 1.775B 1.435B 901.935M 990.266M 1.068B 1.222B 491.738M 91.125M 96.53M 47.044M 27.979M 28.494M 13.147M — — — — — — — — —
Net profit -225.68M -53.224M -188.863M -328.405M -30.143M 30.586M -314.925M -153.04M -308.87M -25.083M -30.028M -171.666M -114.407M -29.048M -1.283M -18.926M -30.113M — — -648K -186K -1.926M -5.793M -10.358M -8.785M -7.165M
Free cash flow -190.82M -208.499M -44.472M -119.767M 6.181M 5.794M -185.263M -136.999M -138.604M 13.499M 153.178M -95.113M -62.154M -26.887M -20.453M -19.486M -23.508M — — — — — — — -8.503M -5.529M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 1.26 1.47 1.51 1.25 4.81 3.95 1.47 3.01 4.9 9.3 10.05 9.99 8.44 4.7 4.83 3.65 1.68 1.41 2.79 — — — — — — —
Price performance 12m -0.14 -0.03 0.21 -0.74 0.22 1.69 -0.51 -0.39 -0.47 -0.07 0.01 0.18 0.8 -0.03 0.32 1.17 0.19 -0.49 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 220M 166M 144M 135M 286M 260M 127M 123M 118M 90.3M
↳ YoY growth +13.6% -24.9% -13.1% -6.5% +112.7% -9.3% -51.0% -3.1% -4.3% -23.5%
↳ 5y CAGR +77.4% +50.9% +48.7% +46.5% +8.1% +3.3% -5.1% -3.0% -2.6% -20.6%
Borrowings, current (USD) 12M 11.9M 5.85M — — — 1.72M 1.99M 1.38M 344M
Borrowings, non-current (USD) 717,000 1.57M 4.65M 3.91M 3.84M — 9.29M 7.73M 3M 2.26M
Lease liabilities (USD) — — — 46.5M 44M 49.9M 49.5M 77.2M 67.2M 52.8M
Cash and deposits (USD) 169M 91.5M 96.5M 85.5M 72.2M 135M 153M 95.9M 427M 364M
Intangible assets (USD) 764M 684M 614M 529M 475M 322M 824M 740M 617M 516M
Right-of-use assets (USD) — — — 39.4M 37.7M 44.2M 38.7M 68.1M 54M 46.9M
Net debt (borrowings + leases - cash) (USD) -156M -78M -86M -35.1M -24.3M — -92.7M -8.92M -355M 34.6M
Cash flow detail
Operating cash flow (USD) 32M -92.1M -109M -173M 39.5M 38.3M -95.2M -28.2M -183M -179M
Purchases of property, plant and equipment (USD) -18.5M -46.5M -27.9M -12.7M -33.7M -32.2M -24.6M -16.3M -25M -12.3M
Purchases of intangible assets (USD) -5M 0.00 0.00 — — — — — — —
Change in receivables (cash effect) (USD) -25.6M 58M 20.4M 7.38M -150M 5.23M 129M 3.41M -220,000 30.2M
Change in inventories (cash effect) (USD) -6.61M -3.54M 4.59M -12.1M -77.6M 30.7M 13.7M 15.2M 4.22M -4.12M
Change in payables (cash effect) (USD) -19.8M 20.2M -26.1M 15.6M 37.2M -10.8M -9.39M 2.83M -20.7M -14.2M
Share buybacks (cash effect) (USD) — — — — — — 0.00 0.00 -90.2M -47M
Interest paid (cash effect) (USD) -2.89M -1.31M -2.08M -11.9M -10.9M -8.52M -7.42M -8.14M -20.9M -37.9M
Income taxes paid (cash effect) (USD) 27.1M -5.42M 1.41M -2.67M 903,000 -5.97M -8.04M -3.71M -10M -24.5M
Share-based compensation (USD) 42.7M 28.3M 21.8M 13.4M 8.95M 13.6M 18.5M 11.4M 11M 10.7M
Operating cash flow before change in receivables (USD) 57.7M -150M -130M -180M 190M 33.1M -224M -31.6M -183M -209M
Free cash flow (OCF - PPE - intangibles) (USD) 8.5M -139M -137M -185M 5.79M 6.18M -120M -44.5M -208M -191M
Income detail
Research and development expense (USD) 111M 125M 126M 118M 75.3M 76.9M 73.9M 89.6M 105M 124M
↳ 5y CAGR +57.8% +45.0% +18.4% +7.1% -5.4% -7.1% -10.0% -6.5% -2.2% +10.5%
Total comprehensive income (USD) -29.6M -282M -173M -317M 48.4M -56.4M -341M -184M -71.3M -191M
Comprehensive income to owners (USD) — -279M -173M -317M 48.4M -56.4M -341M -184M -71.3M -191M
Provision for credit losses (USD) 83.5M 107M 700,000 500,000 200,000 400,000 300,000 300,000 100,000 800,000
Credit cost ratio (credit losses / average receivables) (%) 40.3% 55.6% 0.5% 0.4% 0.1% 0.1% 0.2% 0.2% 0.1% 0.8%
Reported Mar 1, 2017 Mar 2, 2020 Mar 2, 2020 Mar 2, 2020 Apr 28, 2021 Mar 1, 2022 Mar 3, 2025 Mar 3, 2025 Mar 3, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 04, 2026 4:23pm EST

Related Documents

Earnings Webcast Audio

10-Q HTML XBRL Zip

Conference Call to Begin Today at 4:30 p.m. ET

MIAMI, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 and Recent Business Highlights

  • **OPKO enters into agreement with Labcorp for the sale of substantially all remaining BioReference diagnostic operations.**The agreement provides for $722 million in cash consideration at closing, subject to adjustments based on business revenues at closing, and up to $150 million in additional cash consideration over up to ten years based on Labcorp sales of the 4Kscore® test. The transaction remains subject to regulatory approvals and customary closing conditions.

  • **OPKO expands strategic relationship with HealthCare Royalty through $125 million financing.**OPKO issued an additional $125 million aggregate principal amount of senior secured royalty notes. The amended financing framework includes specified royalty payments receivable under OPKO’s license agreement with Eli Lilly and Company (“Lilly”) related to mazdutide.

  • **OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly.**The first participant has been dosed in a first-in-human Phase 1/2a clinical trial of OPK-8801001, an investigational, long acting human growth hormone receptor antagonist being developed for the treatment of acromegaly. The study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of OPK-8801001. OPK-8801001 is being developed using OPKO Biologics’ stabilizer based technology to extend biological half life and reduce injection frequency, with the goal of once weekly administration. In preclinical studies, OPK-8801001 produced robust, dose dependent sustained suppression of insulin-like growth factor-1 (IGF-1), a key marker of disease activity in acromegaly.

  • ModeX completes enrollment in MDX2301 Phase 1 clinical trial. MDX2301 is a tetravalent bispecific antibody designed to neutralize known SARS-CoV-2 variants while maintaining breadth and reducing the potential for resistance. The Phase 1 trial is evaluating safety, tolerability, and pharmacokinetics across multiple routes of administration in healthy volunteers and immunocompromised adults at high risk for severe COVID-19. This trial is being funded by the Biomedical Advanced Research and Development Authority (BARDA). Early data is expected to be presented in late 2026 or early 2027.

  • ModeX continues enrollment in MDX2001 and MDX2004 Phase 1 trials. MDX2001, a tetraspecific T cell engager directed to solid tumors that express Trop2 and c-Met, continues to enroll participants in its Phase 1 study as planned. MDX2004, a trispecific immune rejuvenator that stimulates through CD3, CD28 and 4-1BBL, also continues Phase 1 enrollment as planned at sites in Australia and Israel. We expect to report initial safety, tolerability, pharmacokinetic and immune data for both studies in the first half of 2027.

  • ModeX continues enrolling patients in MDX2003 Phase 1 clinical trial in relapsed or refractory B-cell lymphoma. MDX2003 (CD19 x CD20 x CD3 x CD28) is a novel tetraspecific T-cell engager-expander designed to optimize sustained T-cell function and address the two most common and validated targets in lymphomas and leukemias. The MDX2003 Phase 1 study is evaluating safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in adults with B-cell lymphomas through dose-escalation and dose-expansion cohorts. B-cell lymphoma, a form of non-Hodgkin lymphoma, represents the most common lymphoma subtype, accounting for approximately 85% of cases.

  • OPKO continues U.S. enrollment in the Phase 1/2a study of OPK-88006, a dual GLP-1/glucagon receptor agonist. The study is evaluating the safety and pharmacokinetics of single ascending doses in healthy volunteers and changes in pharmacodynamic parameters with dose escalation to a desired maintenance dose over 20 weeks treatment in participants with presumed metabolic dysfunction-associated steatohepatitis. Single ascending dosing portion of the trials show favorable safety and tolerability 3 dose levels in 24 participants. The multiple ascending dose portion of the trial is actively enrolling subjects at 4 qualified study sites.

Third Quarter Financial Results

**New presentation of continuing and discontinued operations.**Following the Board of Directors’ September 30, 2026 approval of a plan to sell substantially all remaining BioReference diagnostic operations to Labcorp, OPKO classified the related disposal group as held for sale. Because the planned disposition represents a strategic shift that will eliminate substantially all remaining diagnostic operations, BioReference’s historical results are presented as discontinued operations for all periods shown, and prior period amounts have been recast. OPKO’s continuing operations are now reported through two segments, Global Products and Innovative Biotech, with unallocated corporate costs presented separately. This presentation is intended to provide a clearer view of the biopharmaceutical businesses that will remain with OPKO following the planned transaction.

  • Consolidated continuing operations. Revenue in the third quarter of 2026 increased 16% to $65.4 million from $56.4 million in the prior-year quarter, principally resulting from higher royalty revenue from Lilly, increased sales of Rayaldee and growth in international operations. Operating loss during the third quarter of 2026 decreased to $31.4 million from $33.6 million in the comparable 2025 period. Non-cash depreciation, amortization and equity-based compensation expense included in operating income (loss) was $20.7 million in the third quarter of 2026 compared with $20.5 million for the 2025 quarter. Net loss from continuing operations during the third quarter of 2026 was $35.5 million, or $0.05 per share, compared to $33.0 million, or $0.04 per share, in the third quarter of 2025.

  • Global Products. Segment revenue for the third quarter of 2026 increased to $48.4 million from $39.4 million for the 2025 period. Revenue from products for the third quarter of 2026 was $41.8 million compared with $37.7 million for the comparable 2025 period. Rayaldee revenue in the third quarter of 2026 increased to $8.6 million from $7.5 million in the 2025 period, due to favorable gross-to-net adjustments as a result of changes to our Medicare Coverage. Revenue from international operations increased approximately $3.0 million, reflecting stronger performance in certain international markets, including our animal health business, and higher EirGen revenue driven by increased sales volumes and favorable product mix; this also included an approximately $0.7 million favorable foreign currency impact, primarily from appreciation of the Chilean peso and Mexican peso against the U.S. dollar. Licensing, collaboration and other revenue for the third quarter of 2026 increased to $6.6 million from $1.8 million for the 2025 quarter, primarily driven by $5.8 million of royalty revenue from Lilly, partially offset by lower contract manufacturers’ commercial milestone revenue recognized by EirGen. Total costs and expenses for the third quarter of 2026 were $42.4 million compared with $40.6 million for the 2025 quarter. Segment operating income for the third quarter of 2026 was $6.0 million compared with an operating loss of $1.2 million for the third quarter of 2025. Non-cash depreciation, amortization and equity-based compensation expense included in operating income (loss) was $6.3 million compared with $5.5 million.

  • Innovative Biotech. Licensing, collaboration and other revenue was $17.0 million in both the third quarter of 2026 and 2025. Lower BARDA revenue in the third quarter of 2026 of $7.5 million compared with $8.2 million during the 2025 quarter was substantially offset by $0.8 million of collaboration revenue under the Regeneron agreement, while Pfizer royalty revenue was relatively consistent. Research and development expense for the third quarter of 2026 increased to $30.4 million from $26.3 million during the 2025 quarter, primarily reflecting increased investment in ModeX development programs. Total costs and expenses during the third quarter of 2026 were $43.8 million compared with $39.5 million during the third quarter of 2025. Segment operating loss during the third quarter of 2026 was $26.8 million compared with $22.5 million during the 2025 quarter. Non-cash depreciation, amortization and equity-based compensation expense included in operating income (loss) was $13.4 million compared with $14.0 million during 2025.

  • Corporate. Unallocated corporate operating loss during the third quarter of 2026 was $10.6 million compared with $9.9 million during 2025, primarily reflecting employee-related and general administrative expenses not allocated to the operating segments. Non-cash depreciation, amortization and equity-based compensation expense included in operating income (loss) was approximately $1.0 million in each of the third quarters of 2026 and 2025.

  • Discontinued operations. BioReference generated revenue during the third quarter of 2026 of $71.8 million compared with $95.2 million during the third quarter of 2025. Loss from discontinued operations, net of tax, during the third quarter of 2026 was $18.0 million compared with income of $54.6 million in the prior-year quarter. The 2025 result included a $101.6 million gain on the sale of BioReference’s oncology diagnostics business and related clinical testing services assets to Labcorp.

  • Liquidity and capital allocation. Cash, cash equivalents and restricted cash were $403.2 million as of September 30, 2026. During the quarter, OPKO received approximately $123.1 million of net proceeds from the additional royalty financing and approximately $19.8 million from the release of escrow funds related to the September 2025 oncology transaction. OPKO repurchased 7,050,000 shares during the quarter for approximately $10.6 million. As of September 30, 2026, approximately $115.7 million had been deployed under the $200 million share repurchase authorization, leaving approximately $84.3 million available.

Financial Guidance

In light of the pending transaction with Labcorp, OPKO has withdrawn its previously issued guidance for services revenue and total costs and expenses due to uncertainty regarding the timing of the potential closing and its impact on OPKO’s financial results. OPKO will continue to provide guidance for its continuing operations.

Scroll to view ↔

| (in millions) | For the three months ended****December 31, 2026 | For the yearendedDecember 31, 2026 |

| | Low | High | Low | High |

| Services revenue | Withdrawn |

| Product revenue | $ | 41.0 | | $ | 46.0 | | $ | 164.0 | | $ | 169.0 | |

| IP and other revenue | | 21.0 | | | 27.0 | | | 105.0 | | | 110.0 | |

| Total revenue | $ | 62.0 | | $ | 72.0 | | $ | 268.0 | | $ | 278.0 | |

| Included in revenue: | | | | | | |

| Pfizer gross profit share | $ | 12.5 | | $ | 15.0 | | $ | 34.0 | | $ | 37.0 | |

| BARDA | | 3.0 | | | 5.0 | | | 20.0 | | | 22.0 | |

| Total costs and expenses [from continuing operations] | | 100.0 | | | 105.0 | | | 390.0 | | | 395.0 | |

| R&D included in costs and expenses | | 32.0 | | | 35.0 | | | 125.0 | | | 130.0 | |

| Income/(loss) from discontinued operations | | (35.0 | ) | | (45.0 | ) | | (60.0 | ) | | (70.0 | ) |

| | | | | | | | | | | | | |

— Tables to Follow —

Summary of Revenues

Scroll to view ↔

| (in millions, unaudited) | Three months ended****Sept. 30, 2026 | Three months ended****Sept. 30, 2025 | Nine months ended****Sept. 30, 2026 | Nine months ended****Sept. 30, 2025 |

| Pharmaceutical revenue | | | | | | | | | | | | |

| International Operations | $ | 33.2 | | $ | 30.2 | | $ | 99.8 | | $ | 92.2 | |

| Rayaldee | | 8.6 | | | 7.5 | | | 23.0 | | | 21.0 | |

| Revenue from products | | 41.8 | | | 37.7 | | | 122.8 | | | 113.2 | |

| NGENLA royalty and profit sharing, and cost sharing | | 8.7 | | | 8.8 | | | 21.2 | | | 19.5 | |

| BARDA | | 7.5 | | | 8.2 | | | 16.5 | | | 21.6 | |

| Regeneron | | 0.8 | | | — | | | 2.9 | | | — | |

| Other royalties and milestones | | 6.6 | | | 1.7 | | | 43.1 | | | 4.9 | |

| Licensing, collaboration and other revenue | | 23.6 | | | 18.7 | | | 83.7 | | | 46.0 | |

| Total revenues | $ | 65.4 | | $ | 56.4 | | $ | 206.5 | | $ | 159.2 | |

| | | | | | | | | | | | | |

Summary of Revenue and Segment Operating Results

Scroll to view ↔

| (in millions, unaudited) | Three months ended****Sept. 30, 2026 | Three months ended Sept. 30, 2025 | Nine months ended****Sept. 30, 2026 | Nine months ended****Sept. 30, 2025 |

| Global Products revenue | $ | 48.4 | | $ | 39.4 | | $ | 165.9 | | $ | 118.1 | |

| Innovative Biotech revenue | | 17.0 | | | 17.0 | | | 40.6 | | | 41.1 | |

| Total revenues | $ | 65.4 | | $ | 56.4 | | $ | 206.5 | | $ | 159.2 | |

| Global Products operating income (loss) | $ | 6.0 | | $ | (1.2 | ) | $ | 35.6 | | $ | (8.6 | ) |

| Non-cash depreciation, amortization and equity based compensation expense included in operating income (loss) | $ | 6.3 | | $ | 5.5 | | $ | 17.9 | | $ | 16.4 | |

| Innovative Biotech operating loss | $ | (26.8 | ) | $ | (22.5 | ) | $ | (84.2 | ) | $ | (77.4 | ) |

| Non-cash depreciation, amortization and equity based compensation expense included in operating income (loss) | $ | 13.4 | | $ | 14.0 | | $ | 41.0 | | $ | 41.5 | |

| Corporate operating loss | $ | (10.6 | ) | $ | (9.9 | ) | $ | (32.8 | ) | $ | (32.9 | ) |

| Non-cash depreciation, amortization and equity based compensation expense included in operating income (loss) | $ | 1.0 | | $ | 1.0 | | $ | 2.9 | | $ | 3.0 | |

| Consolidated operating loss | $ | (31.4 | ) | $ | (33.6 | ) | $ | (81.4 | ) | $ | (118.9 | ) |

| Non-cash depreciation, amortization and equity based compensation expense included in operating income (loss) | $ | 20.7 | | $ | 20.5 | | $ | 61.8 | | $ | 60.9 | |

| | | | | | | | | | | | | |

Results of Discontinued Operations

Scroll to view ↔

| (in millions, unaudited) | Three months ended****Sept. 30, 2026 | Three months ended****Sept. 30, 2025 | Nine monthsendedSept. 30, 2026 | Nine months ended****Sept. 30, 2025 |

| Revenue | $ | 71.8 | | $ | 95.2 | | $ | 218.5 | | $ | 299.2 | |

| Operating income (loss) | $ | (18.8 | ) | $ | 81.6 | | $ | (26.7 | ) | $ | 39.8 | |

| Income (loss) before income taxes | $ | (18.7 | ) | $ | 82.4 | | $ | (26.1 | ) | $ | 43.6 | |

| Income (loss) from discontinued operations, net of tax | $ | (18.0 | ) | $ | 54.6 | | $ | (25.6 | ) | $ | 14.6 | |

| | | | | | | | | | | | | |

Condensed Consolidated Statements of Operations

Scroll to view ↔

| (in millions, except per-share data; unaudited) | Three months ended****Sept. 30, 2026 | Three months ended****Sept. 30, 2025 | Nine months ended****Sept. 30, 2026 | Nine months ended****Sept. 30, 2025 |

| Revenue from products | $ | 41.8 | | $ | 37.7 | | $ | 122.8 | | $ | 113.2 | |

| Licensing, collaboration and other revenue | | 23.6 | | | 18.7 | | | 83.7 | | | 46.0 | |

| Total revenues | | 65.4 | | | 56.4 | | | 206.5 | | | 159.2 | |

| Cost of revenue | | 23.3 | | | 21.4 | | | 70.7 | | | 69.3 | |

| Selling, general and administrative | | 24.8 | | | 22.3 | | | 73.6 | | | 69.5 | |

| Research and development | | 32.2 | | | 29.8 | | | 94.3 | | | 90.3 | |

| Amortization of intangible assets | | 16.5 | | | 16.5 | | | 49.3 | | | 49.0 | |

| Total costs and expenses | | 96.8 | | | 90.0 | | | 287.9 | | | 278.1 | |

| Operating loss | | (31.4 | ) | | (33.6 | ) | | (81.4 | ) | | (118.9 | ) |

| Non-cash depreciation, amortization and equity based compensation expense included in operating income (loss) | | 20.7 | | | 20.5 | | | 61.8 | | | 60.9 | |

| Other expense, net | | (6.4 | ) | | (7.4 | ) | | (23.5 | ) | | (119.2 | ) |

| Loss before income taxes and investment losses | | (37.8 | ) | | (41.0 | ) | | (104.9 | ) | | (238.0 | ) |

| Income tax benefit | | 7.3 | | | 8.0 | | | 18.7 | | | 29.0 | |

| Loss from investments in investees | | (5.0 | ) | | — | | | (5.0 | ) | | — | |

| Net loss from continuing operations | $ | (35.5 | ) | $ | (33.0 | ) | $ | (91.2 | ) | $ | (209.0 | ) |

| Income (loss) from discontinued operations, net of tax | | (18.0 | ) | | 54.6 | | | (25.6 | ) | | 14.6 | |

| Net income (loss) | $ | (53.5 | ) | $ | 21.6 | | $ | (116.8 | ) | $ | (194.4 | ) |

| Loss per share from continuing operations, basic and diluted | $ | (0.05 | ) | $ | (0.04 | ) | $ | (0.12 | ) | $ | (0.28 | ) |

| Income (loss) per share from discontinued operations, basic and diluted | $ | (0.02 | ) | $ | 0.07 | | $ | (0.03 | ) | $ | 0.02 | |

| Net income (loss) per share, basic and diluted | $ | (0.07 | ) | $ | 0.03 | | $ | (0.16 | ) | $ | (0.26 | ) |

| | | | | | | | | | | | | |

Condensed Consolidated Balance Sheets

Scroll to view ↔

| (in millions, unaudited) | September 30, 2026 | December 31, 2025 |

| Cash, cash equivalents and current restricted cash | $ | 390.2 | | $ | 369.1 | |

| Accounts receivable, net | | 80.2 | | | 90.3 | |

| Inventory, net | | 50.6 | | | 52.7 | |

| Other current assets | | 37.2 | | | 56.7 | |

| Current assets held for sale | | 248.1 | | | 13.1 | |

| Total current assets | | 806.3 | | | 581.9 | |

| Noncurrent assets held for sale | | — | | | 244.5 | |

| Noncurrent assets | | 1,074.0 | | | 1,105.5 | |

| Total assets | $ | 1,880.3 | | $ | 1,931.9 | |

| Total current liabilities | $ | 162.4 | | $ | 146.7 | |

| Long-term portion of convertible notes | | 92.5 | | | 85.0 | |

| Senior secured royalty financing | | 370.2 | | | 246.4 | |

| Other noncurrent liabilities | | 139.0 | | | 185.8 | |

| Total liabilities | | 764.1 | | | 663.9 | |

| Total shareholders’ equity | | 1,116.2 | | | 1,268.0 | |

| Total liabilities and shareholders’ equity | $ | 1,880.3 | | $ | 1,931.9 | |

| | | | | | | |

Conference Call and Webcast Information

OPKO’s senior management will provide a business update, discuss third quarter financial results and answer questions during a conference call and live audio webcast today beginning at 4:30 p.m. ET. Participants are encouraged to pre-register for the conference call using the registration link provided by OPKO Investor Relations. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International).

A telephone replay will be available until November 11, 2026, by dialing 855-669-9658 (U.S.) or 412-317-0088 (International) and providing passcode 3222736. A webcast replay will be available through OPKO’s Investor Relations website.

About OPKO Health

OPKO Health, Inc. is a multinational biopharmaceutical company focused on developing and delivering therapeutics for serious diseases across global markets. The company’s research and development programs include multispecific antibody technologies and proprietary long-acting peptide and protein engineering capabilities. OPKO also operates specialty pharmaceutical businesses across several international markets. For more information, visit www.opko.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995, including statements regarding whether the proposed transaction with Labcorp will close and whether we will receive the anticipated purchase price; the anticipated benefits of the transaction; potential additional consideration tied to 4Kscore® revenue; the benefits of the HCRs amended financing, including continued royalty stream from mazdutide; the progress, timing and results of clinical and preclinical programs; expected data disclosures; whether the products under development will be safe, tolerable and effective; whether the products under development will be able to be commercialized and marketed; and OPKO’s business, financial condition, strategies and prospects. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, including the risks described in OPKO’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and OPKO undertakes no obligation to update them except as required by law.

October 28, 2026 8:52am EDT

MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc.(OPKO) (NASDAQ: OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the third quarter 2026 on Wednesday, November 4, 2026. OPKO’s senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance.

CONFERENCE CALL & WEBCAST INFORMATION

OPKO encourages participants to pre-register for the conference call using this link. Participants who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed through OPKO’s Investor Relations here.

A telephone replay will be available until November 11, 2026, by dialing 855-669-9658 (U.S.) or 412-317-0088 (International) and providing the passcode 3222736. A webcast replay will be available beginning approximately one hour after the completion of the live conference call through OPKO’s Investor Relations here.

About OPKO Health OPKO Health, Inc. is a multinational biopharmaceutical company focused on developing and delivering therapeutics for serious diseases across global markets. The company’s research and development programs include multispecific antibody technologies, in vivo CAR-T delivered through antibody-guided lipid nanoparticles, and proprietary long-acting peptide and protein engineering capabilities. OPKO also operates specialty pharmaceutical businesses across several international markets.

October 27, 2026 8:00am EDT

First-in-human study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamic activity of OPK-8801001, a potential once-weekly, long-acting growth hormone receptor antagonist

KIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (NASDAQ: OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial of OPK-8801001, an investigational, long acting human growth hormone receptor antagonist being developed for the treatment of acromegaly. The study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of OPK-8801001.

OPK-8801001 is being developed using OPKO Biologics’ stabilizer based technology to extend serum half life and reduce injection frequency, with the goal of once weekly administration. In preclinical studies, OPK-8801001 produced robust, dose dependent sustained suppression of insulin-like growth factor-1 (IGF-1), a key marker of disease activity in acromegaly. In vitro studies also demonstrated potent growth hormone receptor antagonism.

“Dosing the first participant marks an important milestone for OPK-8801001 and for OPKO Biologics’ commitment to advancing differentiated therapies for patients with serious endocrine disorders,” said Laura Moschcovich, Ph.D., General Manager of OPKO Biologics. “OPK-8801001 was designed to combine a potent growth hormone receptor antagonist with a long acting stabilizer intended to support less frequent administration. We look forward to evaluating its clinical performance and its potential to improve disease control while reducing treatment burden for people living with acromegaly.”

“The initiation of this first in human study reflects OPKO’s strategy of applying innovative technologies to well-established biological pathways to satisfy persistent meaningful patient needs,” said Phillip Frost, M.D., Chairman and CEO of OPKO Health. “We are pleased to support OPKO Biologics as it advances OPK-8801001 into clinical development and as it continues to build a differentiated endocrinology based pipeline.”

About OPK-8801001 OPK-8801001 is an investigational long-acting hGH receptor antagonist being developed by OPKO Biologics for the treatment of acromegaly. It uses stabilizer-based technology intended to extend serum half life and reduce injection frequency, with the goal of once weekly administration. Preclinical data presented at ENDO 2026 showed robust, dose-dependent and sustained IGF-1 suppression in vivo and approximately 20-fold greater growth hormone receptor antagonism in vitro compared with pegvisomant.

About Acromegaly Acromegaly is a rare endocrine disorder caused by excess growth hormone, most often due to a benign tumor of the pituitary gland. The condition leads to elevated IGF-1 levels and may be associated with serious complications, including hypertension, diabetes and cardiovascular disease. Despite available therapies, there remains a need for treatment options that provide effective disease control while reducing the burden of ongoing therapy.

About OPKO Biologics OPKO Biologics is a clinical stage company developing next generation, bio-better, long-acting versions of therapeutic protein and peptide drug candidates using CTP, reversible PEGylation and stabilizer-based technologies. Its pipeline includes candidates for endocrine and gastrointestinal indications, including acromegaly, hypoparathyroidism and short bowel syndrome. OPKO Biologics, an OPKO Health company (NASDAQ: OPK), is based in Kiryat Gat, Israel. For more information, visit www.opkobiologics.com.

About OPKO Health OPKO Health, Inc. is a multinational biopharmaceutical company focused on developing and delivering therapeutics for serious diseases across global markets. The company’s research and development programs include multispecific antibody technologies, in vivo CAR-T delivered through antibody-guided lipid nanoparticles, and proprietary long-acting peptide and protein engineering capabilities. OPKO also operates specialty pharmaceutical businesses across several international markets. For more information, visit www.opko.com.

Cautionary Statement Regarding Forward-Looking Statements This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the clinical development, safety, tolerability, pharmacokinetics, pharmacodynamic activity, potential efficacy, dosing profile and commercial potential of OPK-8801001. Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, the possibility that clinical development may be delayed or unsuccessful; that results observed in preclinical studies may not be replicated in clinical trials; that regulatory authorities may not approve OPK-8801001; and the risks described in OPKO Health’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and subsequent reports on Form 10-Q, including, in each case under the headings Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations. OPKO Health undertakes no obligation to update any forward-looking statement, except as required by law.

Investor and Media Contact OPKO Health, Inc. [email protected] 305-575-4100

Alliance Advisors IR Vivian Cervantes [email protected] 973-873-7724

Primary Logo

Source: OPKO Health, Inc.

Released October 27, 2026

Sign up to receive company updates straight to your inbox.

Sign Up for Email Alerts

Prompts

Opko Health, Inc. (ticker OPK), listed in United States.

Company History

Date Change Detail
Jun 9, 2015 Acquired Acquired Bio Reference Laboratories Inc (CIK 792641). Its filings from before the deal are on its own company page, not shown here.
Aug 9, 2013 Acquired Acquired Prolor Biotech, Inc. (CIK 1268659). Its filings from before the deal are on its own company page, not shown here.
Jul 16, 2007 Renamed eXegenics Inc → OPKO HEALTH, INC.
Nov 14, 2001 Renamed CYTOCLONAL PHARMACEUTICS INC /DE → eXegenics Inc

ETFs Holding Opko Health, Inc.

ETF Weight in ETF Shares Market value As of
DFAC 0.00% 303,828 $ 507.393K Nov 12, 2026
AVSC 0.00% 63,266 $ 102.491K Nov 16, 2026